Cited by 163Pancreatic and Hepatic Oncology ResearchPancreatic function and diabetesProtein Kinase Regulation and GTPase Signaling

Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia

Open access
Shi, G, DiRenzo, D, Qu, C, Barney, D, Miley, D, Konieczny, S F·2013·Oncogene

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers owing to a number of characteristics including difficulty in establishing early diagnosis and the absence of effective therapeutic regimens. A large number of genetic alterations have been ascribed to PDAC with mutations in the KRAS2 proto-oncogene thought to be an early event in the progression of disease. Recent lineage-tracing studies have shown that acinar cells expressing mutant Kras(G12D) are induced to transdifferentiate, generating duct-like cells through a process known as acinar-ductal metaplasia (ADM). ADM lesions then convert to precancerous pancreatic intraepithelial neoplasia (PanIN) that progresses to PDAC over time. Thus, understanding the earliest events involved in ADM/PanIN formation would provide much needed information on the molecular pathways that are instrumental in initiating this disease. As studying the transition of acinar cells to metaplastic ductal cells in vivo is complicated by analysis of the entire organ, an in vitro three dimensional (3D) culture system was used to model ADM outside the animal. Kras(G12D)-expressing acinar cells rapidly underwent ADM in 3D culture, forming ductal cysts that silenced acinar genes and activated duct genes, characteristics associated with in vivo ADM/PanIN lesions. Analysis of downstream KRAS signaling events established a critical importance for the Raf/MEK/ERK pathway in ADM induction. In addition, forced expression of the acinar-restricted transcription factor Mist1, which is critical to acinar cell organization, significantly attenuated Kras(G12D)-induced ADM/PanIN formation. These results suggest that maintaining MIST1 activity in Kras(G12D)-expressing acinar cells can partially mitigate the transformation activity of oncogenic KRAS. Future therapeutics that target both the MAPK pathway and Mist1 transcriptional networks may show promising efficacy in combating this deadly disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/onc.2012.210

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Stabilized expression of PTF1A and MIST1 inhibits PanIN formation in the context of mutant KRAS expression.

    “stabilized expression of PTF1A and MIST1 inhibit PanIN formation in the context of mutant KRAS expression122,123.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [123]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Shi, G., DiRenzo, D., Qu, C., Barney, D., Miley, D., & Konieczny, S. F.
Affiliations
Purdue University West Lafayette (US)
Corresponding author
Konieczny, S F
Venue
Oncogene
Published
2012-06-04
Volume
32
Issue
15
Pages
1950-1958
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2048669411
Cited by
162
References
47
Citations by year
2026: 7 · 2025: 4 · 2024: 12 · 2023: 14 · 2022: 13 · 2021: 14 · 2020: 12 · 2019: 3 · 2018: 15 · 2017: 13 · 2016: 15 · 2015: 14 · 2014: 15 · 2013: 8 · 2012: 2
FWCI
6.33
Type
journal article
Language
en
Open access
Locations
  • Oncogene (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Purdue University
  • National Institutes of Health
  • National Cancer Institute (R01CA124586, CA124586)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK55489, R01DK055489)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Keywords
acinar-to-ductal metaplasia, pancreatic ductal adenocarcinoma, KRAS G12D, Mist1, Raf/MEK/ERK pathway, MAPK signaling, pancreatic intraepithelial neoplasia, 3D organoid culture, pancreatic cancer initiation
MeSH terms
Animals, Carcinoma in Situ, Cell Line, Cell Transformation, Neoplastic, Metaplasia, Mice, Transgenic, Pancreatic Ducts, Pancreatic Neoplasms, Precancerous Conditions, Signal Transduction, Proto-Oncogene Proteins p21(ras), Carcinoma, Pancreatic Ductal, Extracellular Signal-Regulated MAP Kinases, raf Kinases, Mice, Basic Helix-Loop-Helix Proteins, Acinar Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review